Latest from Sidney Kimmel Cancer Center at Jefferson

Thomas Jefferson University Hospital (Sidney Kimmel Cancer Center at Jefferson) is ranked No. 20 in the Nation in the cancer specialty, according to US News and World Report.
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.
A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and Drexel University has recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.
Two new studies from the laboratory of Dr. Alex Mazo at the Sidney Kimmel Cancer Center at Thomas Jefferson University, along with collaborators from SKCC, the Vickie and Jack Farber Institute for Neuroscience and other institutions, provide new insights into the structure of chromatin and its implications for cellular differentiation.
Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent updates in the treatment of patients with chronic lymphocytic leukemia (CLL).
Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.
Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.
Publication Bottom Border
Border Publication